Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Pharma Becomes First To Set Up India R&D Center

This article was originally published in PharmAsia News

Executive Summary

Daewoong Pharmaceutical has set up a new research and development center in the southern India city of Hyderabad. It is the first time a Korean pharma has established a research facility in India

You may also be interested in...



Eurand Inks Deal With Daewoong To Market Muscle Relaxant in Korea

SHANGHAI - Eurand has signed a license and distribution agreement with Daewoong Pharmaceutical to launch extended-release muscle relaxantAmrix (cyclobenzaprine) in Korea, the Milan-based company announced Aug. 1

Eurand Inks Deal With Daewoong To Market Muscle Relaxant in Korea

SHANGHAI - Eurand has signed a license and distribution agreement with Daewoong Pharmaceutical to launch extended-release muscle relaxantAmrix (cyclobenzaprine) in Korea, the Milan-based company announced Aug. 1

Korea's Pharmaceutical Industry Embraces India

Donga (South Korea) (03/07/07)

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel